Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to gather safety and effectiveness information about a new
formulation of Hydrocortisone (Chronocort®) used to treat patients with a disease called
congenital adrenal hyperplasia (CAH). Hydrocortisone is the man-made version of the hormone
cortisol, which is released in the body following a regular daily pattern. The objective of
the study is to measure the levels of hydrocortisone that are absorbed into the bloodstream
once Chronocort® is taken and what affects it has on other hormones in the body. Since
Chronocort® is anticipated to mimic the same release pattern of cortisol in the body, it is
hoped that patients with CAH will be treated more effectively to manage their disease.